Invion (AU:IVX)
ASX:IVX
IVX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.20
Previous CloseN/A
Volume36.17K
Average Volume (3M)97.01K
Market Cap
AU$6.79M
Enterprise ValueAU$7.28M
Total Cash (Recent Filing)AU$137.54K
Total Debt (Recent Filing)AU$627.68K
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding96,965,320
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Debt / Conservative LeverageHaving no reported debt reduces financing risk and interest burden, a durable strength for a cash-burning biotech. This structural conservatism preserves flexibility to pursue partnerships or raise equity on better terms and lowers short- to medium-term solvency pressure.
Partner-funded Development & Licensing ModelReliance on development funding and licensing provides non-dilutive or milestone-driven cash inflows and aligns R&D incentives with partners. Over 2-6 months this durable model can extend runway and de-risk commercialization by sharing costs and leveraging partner commercial channels.
Proprietary PDT Tech And Research CollaborationsOwning proprietary photodynamic therapy tech and deep academic collaborations creates barriers to entry and supports a pipeline approach. These structural assets sustain long-term R&D potential, enable licensing or co-development deals, and strengthen future commercialization options.
Bears Say
Zero FY2025 RevenueA move to zero reported revenue is a fundamental red flag for durable business health: it signals failure to convert R&D into sales or milestone receipts, undermines internal cash generation, makes sustained operations dependent on external financing or partners, and lengthens time to self-sufficiency.
Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating cash flow drains liquidity and forces repeated external funding. Persistent cash burn reduces strategic optionality, risks dilution or distressed financing, and limits sustained investment in trials or commercialization without clear near-term funding commitments.
Shrinking Equity And Asset BaseEroding equity and declining assets shrink the balance-sheet cushion against setbacks and reduce financial flexibility. Over months this deterioration heightens funding risk, impairs credit or partner negotiation positions, and increases likelihood of dilution to sustain operations.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.07 and its highest was AU$0.20 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$6.79M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 145 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -AU$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.042.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is dedicated to advancing its novel technologies to offer innovative treatment solutions that can improve patient outcomes. The company's core products include its proprietary PDT compounds and related systems that leverage light-activated processes to target and destroy cancer cells.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Options Prices
Currently, No data available
---